No abstract

No abstract

This paper proposes a new method to design a single-layer dual-band circularly polarized (CP) patch antenna with a small frequency ratio. The design consists of one or several pairs of rectangular patches proximity-fed by a 50-Ω microstrip line with an open-circuit termination. By exploiting both capacitive and inductive coupling mechanisms, and both orthogonal radiating modes of these patches, the antenna can be designed to operate at two close resonance frequencies. Due to its simple and single-layer structure, the antenna can be easily adapted with meshed configuration, which is suitable for transparent devices. For verification, a dual-band CP meshed patch antenna with a frequency ratio of 1.12 and two pairs of patch is designed, fabricated, and tested. The measurements show that the antenna prototype provides a |S 11 | < −10-dB bandwidth of 4.82−5.03 GHz (210 MHz) and 5.49−5.78 GHz (290 MHz), axial ratio < 3-dB bandwidth of 4.88−4.93 GHz (50 MHz) and 5.50−5.57 GHz (70 MHz), and broadside realized gains of 9.0 dBic and 8.6 dBic for the lower and upper bands, respectively. INDEX TERMS Single layer, rectangular patch, proximity feed, dual-band, circular polarization, meshed patch.

Background: which method of the expulsion of intrauterine fetal death and fetal anomaly in second trimester is effective, safe, and suitable for pregnant women. Objectives: to evaluate the effectiveness of oral misoprostol and vaginal misoprostol for intrauterine fetal death and fetal anomaly in second trimester pregnancy termination. Materials and Methods: a clinical trial in 108 women experiencing intrauterine fetal death and fetal anomaly during the second trimester in the obstetric department, Can Tho central general hospital in 2014. Excluded criteria: multiple pregnancies, uterus cesarean section scar, and misoprostol contraindication. Intervention: randomized division into two groups: group 1: misoprostol oral, group 2: vaginal misoprostol; dosage as recommended by FIGO. Success was defined as a complete and natural fetal and placenta expulsion without dilation and curettage or other treatment; and healthy hospital discharge. Results: the success rate of group 1 was 75.9%; group 2 was 83.3%. The success rates for fetal conditions of intrauterine fetal death were 74.6%, and the fetal anomaly was 86.7%. In group 1, the success rate in intrauterine fetal death was 63%, fetal anomaly was 88.9%. In group 2, the success rate in intrauterine fetal death was 81.3% and fetal anomaly was 86.4%. The rate of expulsion in the first 24 hours was 78.1% in group 1; 88.9% in group 2, which was not different statistically. Some side effects encountered in the study such as headache, nausea, diarrhea, fever/chills, rash were mainly seen in the oral misoprostol group; all side effects and complications were mild and transient. Related factors to complete expulsion in both groups were gestational age, parity, and fetal conditions. Conclusion: vaginal misoprostol has the same effectiveness and fewer complications than oral misoprostol.